(Total Views: 569)
Posted On: 03/05/2021 6:00:26 PM
Post# of 145882
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
"A recently approved IL-6 blocker used to treat severe to critical hospitalized COVID-19 patients requiring mechanical ventilation reduced mortality by 2% compared to the placebo group. In contrast, leronlimab demonstrated a reduction of 24% in mortality compared to the SoC treated group, which is 12 times better in reducing all cause mortality for critically ill COVID-19 patients."
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)